Why the study?
AF is linked to mitochondrial dysfunction, but no studies had examined the short-term effect of SGLT-2 inhibitor administration in AF.
Does empagliflozin alter the expression of mitochondrial regulatory proteins in human myocardium during short-term atrial tachypacing ex vivo?
Does empagliflozin alter the expression of mitochondrial regulatory proteins in human myocardium during short-term atrial tachypacing ex vivo?
Empagliflozin modulates mitochondrial regulatory proteins and reduces oxygen consumption in human atrial tissue during tachypacing, suggesting a potential mechanism for its benefits in atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Empagliflozin modulates mitochondrial proteins in tachypaced models; leaves open translation to human atrial fibrillation therapy.
Muszyński et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: